LianBio Acquires Two IBD Candidates from Landos in $218 Million Agreement
May 17, 2021 at 07:10 AM EDT
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones. The two assets are novel, oral, gut-restricted agonists, both of which are in trials for ulcerative colitis and Crohn's disease. LianBio was formed by Perceptive Advisors, a US healthcare investor, and Landos was backed by Xontology, which partnered with Perceptive to form two funds that invest in biopharma startups. More details... Stock Symbol: (NSDQ: LABP) Share this with colleagues: // //